very nice phase 1 data for intralesional self-replicating IL12 STX-001 in PD-1 refractory melanoma presented by @ProfGLongMIA; ORR 33% at RP2D w manageable tox and modulation of TME #SITC26
so proud of superstar future oncology fellow @MiaAndreoli for leading this effort!
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma | JCO Oncology Practice https://t.co/dkejlD9nQc
This is a landmark moment in melanoma, cancer immunology, & IO drug development at large. Checkpoint inhibitors have allowed us to uncover & amplify the immune impact of cancer therapies we used for decades (e.g.,chemo, RT). Now, coupled with the powerful mRNA vaccine technology, finally unlocked the potential for personalized immunotherapy. Congrats to @Merck & @moderna_tx Grateful for our patients & research teams that allowed to participate in such a monumental accomplishment!
Happy to share our collaboration led by @jsmithymd across 14 international centers on this study of ICI after progression on TIL in advanced #melanoma.
➡️Post-TIL ICI activity was limited, with ORR 11% and median OS 8.8 months, underscoring the need for novel trials in this setting.
An experimental vaccine from Moderna shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results. https://t.co/HM3RcPYkwG
*fantastic* PFS data for darovasertib & crizotinib in HLA A 02:01 negative metastatic uveal melanoma —huge step forward in an area with immense unmet need 👏🏼 👏🏼 👏🏼 #ASCO26
Today at #ASCO26: MSK’s @jsmithymd shared his rapid oral abstract “A phase 2 trial of IO102-IO103 and nivolumab-relatimab in previously untreated, unresectable #melanoma.”
Join MSK melanoma medical oncologist Dr. @jsmithymd at #ASCO26 as he presents results from a phase 2 trial evaluating IO102-IO103 in combination with nivolumab-relatlimab in patients with previously untreated, unresectable melanoma.
🕒 Saturday, May 30 | 5:36 p.m. CDT
Learn more: https://t.co/icY3htlvVU
a translational tour de force covering the last 15 years in melanoma therapy by dr antoni ribas; immense progress but still lots of work to do 🧬 🧫 @MSKCancerCenter
𝗧𝗵𝗲 𝗪𝗼𝗿𝗹𝗱 𝗠𝗲𝗹𝗮𝗻𝗼𝗺𝗮 𝗗𝗮𝘆 𝗚𝗹𝗼𝗯𝗮𝗹 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 continues with a series of expert-led sessions and presentations, featuring leading clinicians and researchers who highlight emerging therapies, share real-world clinical insights, and explore strategies to advance early detection and improve outcomes in melanoma care worldwide.
𝗝𝗮𝗺𝗲𝘀 𝗦𝗺𝗶𝘁𝗵𝘆(@jsmithymd) discussed emerging cell therapy platforms for advanced melanoma, highlighting innovative adoptive cell therapies and next-generation immune-based strategies that are expanding treatment possibilities for patients with refractory disease.
𝗭𝘂𝗹𝗳𝗶𝗾𝘂𝗲𝗿 𝗢𝘁𝘁𝘆 reviewed current approaches to first-line therapy of metastatic melanoma, focusing on treatment selection, immunotherapy combinations, and factors guiding personalized management in clinical practice.
𝗔𝘅𝗲𝗹 𝗛𝗮𝘂𝘀𝗰𝗵𝗶𝗹𝗱 shared perspectives on how melanoma is treated across Europe, outlining regional practices, evolving therapeutic standards, and the integration of novel systemic therapies into routine care.
𝗭𝗮𝗵𝗿𝗮 𝗠𝗼𝗵𝗮𝗺𝗲𝗱 𝗔𝗵𝗺𝗲𝗱 explored the challenges encountered when clinical guidelines meet real-world practice, emphasizing practical decision-making, resource considerations, and adapting evidence-based recommendations to diverse patient settings.
More insights continue to emerge as the OncoDaily Global Symposium unfolds 🌍
🔴 Live sessions available here:
https://t.co/4NMZycjfsR
https://t.co/CF3q839sVl
#OncoDaily #Cancer #Oncology